^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    onilcamotide (RV001)

    i
    Other names: RV001, RV 001, RV001V
    Company:
    Chosa Oncology
    Drug class:
    Immunostimulant
    Related drugs:
    7ms
    Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial. (PubMed, Vaccines (Basel))
    Men randomized to active treatment with RV001V demonstrated the induction of potent, functionally capable, anti RhoC-CD4+ T cell responses. However, there was no benefit in time to biochemical progression, and no difference in time to the initiation of second-line therapies.
    P2 data • Journal
    |
    CD4 (CD4 Molecule)
    |
    onilcamotide (RV001)